ProfileGDS5678 / 1418429_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 90% 90% 90% 88% 88% 87% 86% 89% 87% 92% 93% 91% 90% 92% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.2589290
GSM967853U87-EV human glioblastoma xenograft - Control 27.1910190
GSM967854U87-EV human glioblastoma xenograft - Control 37.2763690
GSM967855U87-EV human glioblastoma xenograft - Control 47.0963288
GSM967856U87-EV human glioblastoma xenograft - Control 56.8988888
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.3848787
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.3829486
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.9013589
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.6076787
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.7044492
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.9141793
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.5322591
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.2174990
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.6980392